Ziman A, Klapper E, Pepkowitz S, Smith R, Garratty G, Goldfinger D
Department of Transfusion Medicine, Cedars-Sinai Medical Center, B700 Beverly Boulevard, Los Angeles, CA, USA.
Vox Sang. 2002 Aug;83(2):165-6. doi: 10.1046/j.1423-0410.2002.00207.x.
Post-transfusion purpura (PTP) is a rare disorder characterized by severe thrombocytopenia developing seven to 10 days following transfusion of platelet-containing blood components, in a person who was previously sensitized via transfusion or pregnancy. Although most cases of PTP are caused by alloantibodies directed against HPA-1a[(Pl(A1))], this case represents the second example of anti-HPA-5a-associated PTP. A 61-year-old female was diagnosed with acute myocardial infarction and gastrointestinal bleeding and, after receiving six units of packed red cells over 5 days, developed PTP as a result of HPA-5a [Br(b)] antibodies with severe thrombocytopenia (5000/microl). She was successfully treated with intravenous immunoglobulin (IVIG), suggesting that this is a highly effective mode of treatment for PTP, regardless of the antibody implicated.
输血后紫癜（PTP）是一种罕见的疾病，其特征为在先前因输血或妊娠而致敏的个体中，输注含血小板血液成分后7至10天出现严重血小板减少。虽然大多数PTP病例是由针对HPA-1a[（Pl(A1)）]的同种抗体引起的，但该病例是抗HPA-5a相关PTP的第二个实例。一名61岁女性被诊断为急性心肌梗死和胃肠道出血，在5天内接受了6单位浓缩红细胞后，因HPA-5a [Br(b)]抗体导致严重血小板减少（5000/微升）而发生PTP。她通过静脉注射免疫球蛋白（IVIG）成功治愈，这表明无论涉及何种抗体，IVIG都是治疗PTP的一种非常有效的方式。
